Optimi Health produces MDMA and Psilocybin drug products for regulated medical use and supplies them directly to authorized clinics and pharmacies.
MDMA drug products supplied for regulated therapeutic use, primarily for the treatment of post-traumatic stress disorder (PTSD) within authorized clinical programs.
MDMA drug products supplied for regulated therapeutic use, primarily for the treatment of post-traumatic stress disorder (PTSD) within authorized clinical programs.
Psilocybin drug products supplied for regulated therapeutic use, including treatment-resistant depression, within approved medical frameworks.
“Australian psychiatrists are now prescribing Optimi’s GMP-certified MDMA and Psilocybin capsules for therapeutic use. Having two regulated psychedelic drug products reaching clinics and patients is a significant milestone for the company and the industry.”
Optimi Health (CSE: OPTI | OTCQX: OPTHF) provides access to public filings, governance materials, and investor communications.
